REGISTER NOW WITH HYPERTENSION CARE
Sign up to receive information through Hypertension Care, including educational materials and other resources for your patients.Register Here
Proven Power in Moderate Patients in the Matrix Trial
In the pivotal MATRIX Trial, which studied patients with moderate hypertension, a mean systolic blood pressure (SBP) reductions of 27 mm Hg and 16 mm Hg were seen in the BENICAR HCT 40/25 mg and BENICAR 40 mg treatment arms, respectively.1
Please see Important Safety Information, including Boxed Warning regarding Fetal Toxicity on this page.
In addition to offering proven medications
to help pull down patients’ BP, Daiichi
Sankyo offers valuable programs and
educational support for patients.
Daiichi Sankyo is committed to helping your patients work toward their BP goal
Savings That Last Program
The Savings That Last card rewards patient compliance by lowering co-pays over time. Also, as an added benefit, Daiichi Sankyo will pay for up to 3 add-on generic antihypertensives if a patient does not reach BP goal while on an olmesartan-based product.
MATRIX Trial: In an 8-week, randomized, double-blind, placebo-controlled trial, BENICAR HCT 40/25 mg reduced mean BP by 27/22 mm Hg and BENICAR 40 mg reduced mean BP by 16/14 mm Hg from baseline to Week 8. Placebo reduced BP by 3/8 mm Hg. Mean baseline BP was 154/103 mm Hg. Most common adverse reactions in this study (>2%) were dizziness, upper respiratory tract infection, nausea, and hyperuricemia. For more information, please see the MATRIX Trial within the website.
Sign up to receive information through Hypertension Care, including educational
materials and other resources for your patients.
BENICAR, AZOR, and TRIBENZOR are indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which these drugs principally belong. There are no controlled trials demonstrating risk reduction with BENICAR, AZOR, or TRIBENZOR.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals.
BENICAR HCT is indicated for the treatment of hypertension. BENICAR HCT is not indicated for initial therapy.
BENICAR, BENICAR HCT, AZOR, and TRIBENZOR can be used alone or with other antihypertensive agents.
AZOR is indicated as initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals.
Initial therapy with AZOR is not recommended in patients ≥75 years of age or in hepatically impaired patients.
TRIBENZOR is not indicated for the initial therapy of hypertension.
Important Safety Information
for BENICAR®, BENICAR HCT®, AZOR®, and TRIBENZOR®
WARNING: FETAL TOXICITY
- When pregnancy is detected, discontinue BENICAR, BENICAR HCT, AZOR, or TRIBENZOR as soon as possible
- Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See WARNINGS AND PRECAUTIONS: Fetal Toxicity
Do not co-administer aliskiren with BENICAR, BENICAR HCT, AZOR, or TRIBENZOR in patients with diabetes.
BENICAR HCT and TRIBENZOR are contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.
WARNINGS AND PRECAUTIONS
Morbidity in Infants: Children <1 year of age must not receive BENICAR for hypertension.
Fetal Toxicity: BENICAR, BENICAR HCT, AZOR, and TRIBENZOR are Pregnancy Category D.
Hypotension in Volume- or Salt-Depleted Patients: In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (eg, those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with BENICAR, BENICAR HCT, AZOR, or TRIBENZOR.
Impaired Renal Function: Monitor for worsening renal function in patients with renal impairment while on BENICAR, BENICAR HCT, AZOR, or TRIBENZOR.
In patients whose renal function may depend upon the activity of the renin-angiotensin-aldosterone system (eg, patients with severe congestive heart failure), treatment with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death. Similar results may be anticipated in patients treated with BENICAR, BENICAR HCT, AZOR, and TRIBENZOR.
In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported and similar results may be expected with BENICAR, BENICAR HCT, AZOR, or TRIBENZOR.
BENICAR HCT is not recommended in patients with severe renal impairment. Avoid use of TRIBENZOR in patients with severely impaired renal function (creatinine clearance ≤30 mL/min). If progressive renal impairment becomes evident, consider withholding or discontinuing TRIBENZOR.
Sprue-like Enteropathy: Severe, chronic diarrhea with substantial weight loss has been reported in patients taking olmesartan months to years after drug initiation. Intestinal biopsies of patients often demonstrated villous atrophy. If a patient develops these symptoms during treatment with olmesartan, exclude other etiologies. Consider discontinuation of BENICAR, BENICAR HCT, AZOR, or TRIBENZOR in cases where no other etiology is identified.
Hepatic Impairment: Initial therapy with AZOR or TRIBENZOR is not recommended in hepatically impaired patients. In patients with severe hepatic impairment, exercise caution with AZOR and avoid use of TRIBENZOR. Thiazides (a component in BENICAR HCT and TRIBENZOR) should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.
Electrolyte and Metabolic Imbalances: Due to the hydrochlorothiazide (HCTZ) component in BENICAR HCT and TRIBENZOR, observe patients for clinical signs of metabolic, fluid, or electrolyte imbalance.
Hypersensitivity Reaction: Hypersensitivity reactions to HCTZ (a component in BENICAR HCT and TRIBENZOR) may occur in patients with or without a history of allergy or bronchial asthma.
Systemic Lupus Erythematosus: Thiazides (a component in BENICAR HCT and TRIBENZOR) have been reported to cause exacerbation or activation of systemic lupus erythematosus.
Acute Myopia and Secondary Angle-Closure Glaucoma: Thiazides can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Discontinue HCTZ (a component in BENICAR HCT and TRIBENZOR) as rapidly as possible in these patients.
Lithium Interaction: Lithium generally should not be given with thiazides (a component in BENICAR HCT and TRIBENZOR).
Vasodilation: Although vasodilation attributable to amlodipine (a component in AZOR and TRIBENZOR) is gradual in onset, acute hypotension has rarely been reported after oral administration. Patients with severe aortic stenosis may be at particular risk.
Increased Angina and/or Myocardial Infarction: Patients taking AZOR or TRIBENZOR, particularly those with severe obstructive coronary artery disease, may develop increased frequency, duration, or severity of angina or acute myocardial infarction on starting calcium channel blocker therapy or at the time of dose increase.
Laboratory Tests: There was a greater decrease in hemoglobin and hematocrit with AZOR compared to either component alone. Other lab abnormalities may include increased blood creatinine levels and hyperkalemia (olmesartan medoxomil), hepatic enzyme elevations (amlodipine), and increased cholesterol and triglyceride levels (HCTZ).
Non-Steroidal Anti-Inflammatory Agents: Concurrent administration of non-steroidal anti-inflammatory drugs (NSAIDs) may lead to increased risk of renal impairment (including possible acute renal failure) and loss of antihypertensive effect of BENICAR, BENICAR HCT, AZOR, and TRIBENZOR.
Dual Blockade of the Renin-Angiotensin System (RAS): Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Closely monitor blood pressure, renal function and electrolytes in patients on BENICAR, BENICAR HCT, AZOR, or TRIBENZOR and other agents that affect the RAS.
Avoid use of aliskiren with BENICAR, BENICAR HCT, AZOR, or TRIBENZOR in patients with renal impairment (GFR <60 mL/min).
Concurrent Use with Colesevelam Hydrochloride: Concurrent administration of colesevelam hydrochloride with BENICAR, BENICAR HCT, AZOR, or TRIBENZOR reduces the systemic exposure and peak plasma concentration of olmesartan. Consider administering olmesartan at least 4 hours before the colesevelam hydrochloride dose.
Effect of Amlodipine on Simvastatin: Due to increased exposure to simvastatin, when co-administered with amlodipine (a component in AZOR and TRIBENZOR), do not exceed doses of greater than 20 mg daily of simvastatin.
BENICAR: The only adverse reaction that occurred in >1% of patients treated with BENICAR and more frequently than placebo was dizziness (3% vs 1%).
BENICAR HCT: Adverse reactions reported in >2% of patients taking BENICAR HCT and more frequently than placebo included nausea (3% vs 0%), hyperuricemia (4% vs 2%), dizziness (9% vs 2%), and upper respiratory tract infection (7% vs 0%).
AZOR: The only adverse reaction that occurred in ≥3% of patients treated with AZOR and more frequently than placebo was edema.
TRIBENZOR: The most frequently reported adverse reaction was dizziness (5.8% to 8.9%). The other most frequent adverse reactions occurring in ≥2% of patients treated with TRIBENZOR were peripheral edema (7.7%), headache (6.4%), fatigue (4.2%), nasopharyngitis (3.5%), muscle spasms (3.1%), nausea (3.0%), upper respiratory tract infection (2.8%), diarrhea (2.6%), urinary tract infection (2.4%), and joint swelling (2.1%).
USE IN SPECIFIC PATIENT POPULATIONS
Nursing Mothers: Avoid use while nursing; discontinue either nursing or the drug.